The Advantages of Multi-Epitope Tumor Antigens as an Approach to Treating Breast Cancer
Abstract
Dendritic cells (DC) are an integral part of the immune system's response to cancer. A number of clinical trials have been initiated to use these cells in the treatment of melanoma, prostate cancer, and lymphoma. In preparation for treating breast cancer patients with DC, this proposal examines a fundamental issue that needs to be resolved before proceeding with this exciting new therapy. We hypothesized that the processing and presentation of multiple tumor antigen epitopes by DC is a more efficient and effective way of stimulating T cell responses than current HLA-restricted peptide-based methods. The goal of this proposal is to develop practical methods by which immune cells from patients with breast cancer can be used to promote effective anti-tumor responses. In the past year, we have been evaluating the phenotype and functional activity of breast cancer patients' DC in preparation for their use in tumor antigen-presentation. We also have developed a rapid method to assess patient's T cell function prior to treatment. In addition, we have optimized testing procedures to evaluate anti-tumor cytotoxicity. This progress is consistent with the proposal's Statement of Work, and leaves us well-positioned to achieve the next goals of the proposal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADA384035
Entities
People
- Sylvia Kiertscher
Organizations
- University of California, Los Angeles